Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
- DOI
- 10.1185/03007990902918156
- Published
- 2009 Jun
- Container
- Current medical research and opinion
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1185/03007990902918156,
title = {Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.},
author = {Tan Sean P and Chouaid C and Hettler D and Baud M and Hejblum G and Tilleul P},
year = {2009},
journal = {Current medical research and opinion},
doi = {10.1185/03007990902918156},
url = {https://doi.org/10.1185/03007990902918156}
}RIS
TY - JOUR TI - Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. AU - Tan Sean P AU - Chouaid C AU - Hettler D AU - Baud M AU - Hejblum G AU - Tilleul P PY - 2009 JO - Current medical research and opinion DO - 10.1185/03007990902918156 UR - https://doi.org/10.1185/03007990902918156 ER -
APA
P, T. S., C, C., D, H., M, B., G, H., & P, T. (2009). Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.. Current medical research and opinion. https://doi.org/10.1185/03007990902918156
Source records
- pubmed · retrieved 2026-09-25T21:39:02.171Z
- europe-pmc · retrieved 2026-09-25T21:39:02.184Z
- hal · retrieved 2026-09-25T21:39:02.234Z